Bruker Daltonics to Introduce Significant New Products at Pittcon 2003; Company Will Host Press Conference and Analyst Booth Tour.Business Editors/Health/Medical Writers BIOWIRE2K Pittcon 2003 BILLERICA, Mass.--(BUSINESS WIRE)--March 3, 2003 Bruker Daltonics Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BDAL BDAL Battle Doll Angelic Layer (game) ) today announced that it will introduce several significant new life-science products at Pittcon 2003 next week in Orlando, Florida. New products include a novel high-performance benchtop ESI-TOF system described in detail in a simultaneous product press release this morning. Detailed press releases on all new product introductions, including Bruker Daltonics' pioneering new high-field FTMS See Fusion FTMS. systems for proteomics research, will be released on Monday, March 10, 2003 at 7 a.m. EST EST electroshock therapy. EST abbr. electroshock therapy . Bruker Daltonics will host a press conference on Tuesday, March 11, 2003 from 12:00 noon to 1:00 pm at the nearby Peabody Orlando Hotel, convention level. Journalists and editors are asked to RSVP to brenda.prost@bruker.com The Company will also host an analyst tour of its new products at booth 2256 on Monday, March 10, 2003 at 10:15 a.m. The analyst tour will be hosted by President & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Frank Laukien, and is expected to last 45 minutes. To participate, RSVP to michael.willett@bdal.com ABOUT BRUKER DALTONICS Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information about Bruker Daltonics, please visit www.bdal.com. CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of Bruker Daltonics' products, dependence on collaborative partners, suppliers, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. and other risk factors discussed from time to time in Bruker Daltonics' reports or filings with the Securities and Exchange Commission. Bruker Daltonics expressly disclaims any obligation to update the information contained herein. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion